Proteasome biology has taken central stage in cardiac physiology and pathophysiology. The molecular heterogeneity of proteasome subpopulations supports the specificity of proteasome function to degrade diverse substrate repertoires. Unveiling the dynamics of proteasome function should inspire new therapeutic strategies for combating cardiac disease.
Molecular Heterogeneity

Inducible Subunits and Immunoproteasomes
The 20S proteasome is a dimer of 14 subunits each, encoded by as many as 19 distinct genes in eukaryotes (30, 56, 57) . Within the 14 subunits, three are catalytic active. ␤1, ␤2, and ␤5 subunits are the major, conventional isoforms expressed in the mammalian heart, exhibiting nominal caspaselike, trypsin-like, and chymotrypsin-like activities, respectively. Heterogeneity of 20S subunits is implemented at these catalytic centers via the substitution of inducible ␤-subunits-␤1i, ␤2i, and ␤5i-for conventional subunits. Expression and assembly of inducible subunits is stimulated by cytokines, such as of IFN-␥ or TNF-␣ (25, 31) , with the induced proteasome complex being referred to as the immunoproteasome. In many forms of cardiomyopathies, including ischemia-reperfusion injury (10) , myocarditis (82) , isoproterenol-induced hypertrophy (24) , and diabetic cardiomyopathy (99) , inducible subunit expression is significantly elevated. Assembly of 20S proteasome ␤-subunits occurs in an ordered fashion, with ␤2 first, followed by ␤1, ␤5, and ␤7 (48) . During this process, the incorporation of sets of conventional or inducible catalytic subunits is cooperative (18) . Additional studies have demonstrated that the interdependence in assembly exists merely at the level of the monomeric "half-proteasome"; thus mature dimeric 20S proteasomes with both conventional and inducible subunits can be assembled (42) . Alterations in subunit composition regulate the capacity, specificity, and products of proteolysis. The half-life of constitutive proteasomes is about 1 wk (15) , whereas that of immunoproteasomes is ϳ 1 day (35) ; nevertheless, the assembly of either form will have an extended impact. The content of immunoproteasomes exhibits a profound impact on cardiac biology. Genetic deletion of LMP-2 (␤1i-KO) correlates with a loss of ischemic preconditioning-induced cardioprotection (10) . ␤1i-KO correlates with an accumulation of oxidized proteins and a reduction in proteasome activities without significantly changing the expression of other proteasome subunits (20) . This indicates that proteolytic activities and specificities of proteasomes shape the resistance of cardiomyocytes to oxidative stress. ␤2i and ␤5i knockout mice have been established (12) , and specific inhibitors to ␤1i are also available (37) . The full delineation of "detrimental" or "protective" roles by immunoproteasomes will likely benefit from these tools (e.g., in the acute phase of ischemia-reperfusion injury).
Regulatory Complexes
Multiple regulatory complexes co-regulate 20S core particles. The canonical regulatory particle, 19S, awaits a detailed molecular exploration in cardiac muscle. Cardiac 19S subunits span a range of 31-105 kDa, together acting as essential substrate selection gateways. Pioneering characterization of murine cardiac 19S proteasomes by LC-MS/MS identified 19 subunits, including various forms of alternatively spliced Rpn10 subunit (Rpn 10b), an example of functional dynamics in polyubiquitin binding and substrate specificity (30) . Direct assaying of the functional dynamics of 19S remains challenging due to extreme difficulties in isolating labile 19S complexes from cardiac tissue. Recent work demonstrated distinct subpopulations of cardiac 19S complexes in the heart, each exhibiting unique regulatory potencies and associating partners (90) . Understanding the role of 19S complexes is important with respect to disease, since cardiac hypertrophy features elevated association between 19S and 20S (24) .
In addition to 19S, 20S proteasomes are also regulated by a heptameric 11S complex. The 11S may bind 20S alone or in conjunction with 19S (84) , and in cardiac cells 11S associates with both 26S and 20S (30) . Although the in vivo role of 11S remains to be fully delineated, 11S enhances proteolytic capacity in an ATP-independent manner through prying open the 20S catalytic chamber (92) without directly altering catalytic potencies of catalytic ␤-subunits (81) . The function of 11S may be recruited in cardiac pathology, since 11S enhances the degradation of misfolded proteins or peptides (72) . Indeed, the abundance of 11S correlates with the resilience of cardiomyocytes to oxidative stress (68) , and its expression is enhanced in experimental hyperglycemia (68) . Nevertheless, the stoichiometric abundance of 11S vs. other forms (e.g., 26S) remains to be determined in the heart.
A monomeric proteasome activator, PA200, was previously identified in the nuclear region of mammalian cells (87) . As with 11S, the functional impact of PA200 in cardiac biology may become significant during conditions involving ATP depletion (e.g., ischemia) due to its 10-fold enhancement of peptide hydrolysis in an energy-independent fashion. The specific set of substrates regulated by PA200 and their contributions to heart biology remain largely elusive. PA200 complexes to both 20S and 26S proteasomes, and exists as three splice variants: 200 kDa, 160 kDa, and 60 kDa (87) . Proteomic analysis FIGURE 1. Cardiac proteasomes are dynamic and heterogeneous organelles mandated by a diverse substrate repertoire Proteasomes are essential nodes of cardiomyocyte signaling. The functional dynamics of cardiac proteasomes are highly regulated via multifaceted mechanisms. The molecular heterogeneity of proteasome complexes as the basis of their functional diversity manifests as differences in subcellular location, incorporation of inducible subunits, assembly with unique regulatory particles, and posttranslational modifications. There is a growing body of evidence to suggest that the diverse array of regulatory particles complexing to 20S core particles specializes proteasomes to degrade specific substrate repertoires. Thus proteasome heterogeneity fulfills the demand for degradation of diverse substrate repertoires in discrete functional locations within cardiomyocytes.
detected PA200 in cytosolic and nuclear compartments of myocytes, with the major portion in the nuclear compartment (30) , but the functional diversity afforded by these splice variances remains to be elucidated.
Associating Partners
Other than dedicated regulatory complexes described above, associating partners or proteasome interacting partners (PIPs) dynamically associate with proteasomes and alter proteasome function (32, 98) . PIPs can be classified based on function. 1) Poly-ubiquitin chain (poly Ub) receptor proteins (88) exhibit selectivity toward distinct substrates for degradation. Thus a shunting of the substrate repertoire may therefore be achieved via noncovalent regulation. 2) Ubiquitin ligases and deubiquitinases associated with proteasomes warrant additional substrate specificity (17) . 3) Kinases and phosphatases, including PKA, PP2A (98), PP1, and casein kinases (29) , regulate proteasomes via covalent modification of their subunits. PKA is an essential component of the ␤-adrenergic signaling pathway, which rapidly regulates the assembly and activity of 26S and 20S proteasomes (2, 98) . 4) Allosteric regulators of proteasomes elicit effects via diverse routes. PI31 is an endogenous, noncompetitive inhibitor that suppresses proteasomal activity and deters the recruitment of activating complexes (96). The association of PI31 with 20S was recently observed to be increased in heart failure (77) . Conversely, ECM29 stabilizes the association of 20S proteasomes with 19S (43) . Multiple forms of heat shock proteins (HSPs) interact with the proteasomes. Hsp90 associates with proteasome subunits during assembly and subsequent recruitment of 19S (36, 94) . This association also primes proteasomes with elevated resistance to oxidative stress (14) . 5) Anchor or adaptor proteins allocate proteasomes to individual foci in cardiac cells, thus facilitating targeted substrate processing (e.g., FKBP38 anchors proteasomes to organellar membranes) (59) . In addition, proteasomes are clearly associated with myofilaments, with significant enrichment at Z-discs (29, 30) . The molecular nature of this interaction, however, has not been fully delineated.
Subcellular Localization
The structural and functional diversity of distinct subcellular loci within cardiomyocytes requires localized subpopulations of degradation machinery, with each precisely tuned to meet the functional demands of resident subcellular compartments. Subcellular heterogeneity and plasticity of proteasomes at rest and in response to stimuli are relatively unexplored in cardiomyocytes; however, in skeletal satellite cells proteasomes exhibit a high-affinity association with desmin, and a labile association with actin (27) . Before myotube fusion, proteasomes reside in the cytosol, then transiently migrate along intermediate filaments to the nucleus. Myotube fusion and maturation of sarcomeres further redistributes proteasomes into a striated pattern, in concert with Z discs (27) . The striated banding pattern of 20S proteasomes was recently observed in adult cardiac muscle cells (29, 30) , and both 20S and 26S complexes were located in nuclear, cytosolic, and membrane-rich regions of the cardiac cell (30) .
Of particular interest is the heterogeneous distribution of proteasome core particles, regulatory particles, and relative ratios of 20S to 26S in different microdomains of the cell. Inducible subunits ␤1i and ␤5i are enriched in endoplasmic reticulum-associated proteasomes of liver cells (8) , suggesting a demand for specialized proteolytic activities such as antigenic peptide processing in membrane-rich regions. Moreover, the ratio of 26S to 20S proteasomes was significantly larger in nuclear vs. cytosolic regions. 11S␣-/␤-subunits demonstrated a cytosolic and endoplasmic reticulum distribution, whereas 11S␥ was exclusively nuclear (7). Additionally, 11S assembly with 20S was enhanced in the membrane-rich fractions during cardiac hypertrophy and failure, and, in contrast, was depressed in cytosolic fractions in failure (77) . This suggests that there is a redistribution of degradation capacities that is implemented, at least in part, by different regulatory particles that specialize in the proteolysis of disease-specific substrates. Tracking stoichiometries of regulatory complexes within each compartment along the progression of cardiac pathogenesis will provide important insights into cardiac remodeling.
Pharmacological Perturbations and Therapeutic Potential in Cardiology
Perturbation of proteasome function is frequently observed in cardiac pathology (66, 91) , and thus pharmacological manipulation of proteasomes may offer therapeutic benefits. Proteasome inhibitors have demonstrated therapeutic efficacy in treating cancer (16, 62) and inflammatory diseases (53) . The utility of these agents in clinical cardiology is still under investigation in the preliminary research phase. It has been reported that prolonged exposure to proteasome inhibitors used in chemotherapy may lead to deleterious, but reversible, cardiac side effects (33, 89) , thus underscoring the importance of tailoring drug specificity, dose, and length of exposure to avoid cardiac toxicity.
Proteasome inhibition may be protective in cardiac ischemia-reperfusion injury (80) , an observation seemingly inconsistent with studies demonstrating that preservation of proteasome activity is necessary for the recovery of postischemic cardiac function (69) . There are at least two possible mechanisms for this apparent discrepancy: 1) inhibition of proteasome function suppresses the inflammatory response mounted during reperfusion, thus reducing the necrosis of cardiomyocytes (11), or 2) inhibitors may stabilize proteasome complexes under elevated oxidative stress. Proteasome inhibition as a therapeutic strategy has shown promise in minimizing both reperfusion injury and cardiac hypertrophy, albeit via different treatment regimes. Brief periods of exposure were found effective for reducing reperfusion injury, whereas low doses of inhibitors for extended treatment times were effective for regressing hypertrophy (34, 52 ). An extended therapeutic window may be attainable with proteasome inhibitors to allow targeted removal of hypertrophic factors.
Pharmacological inhibitors targeting 20S proteasomes can be categorized into two groups. Competitive inhibitors are peptide mimetics that contain reactive groups that interact with NH 2 termini of catalytic ␤-subunits to physically impede critical threonine residues. The chemical nature of the reactive group is pivotal to the dissociation efficiency, and thus the reversibility, of the inhibitors (41) . Specific inhibitors to a particular subpopulation, such as immunoproteasomes (37), support targeted pharmacological intervention. The second group is comprised of non-competitive inhibitors that do not directly attack the NH 2 -terminal threonine residue (4). Clearance rates of inhibitors have important clinical relevance. Inhibitors with slow clearance rates may be advantageous for treating chronic diseases, such as hypertrophic or diabetic cardiomyopathy, whereas inhibitors with fast clearance rates block acute inflammatory responses following ischemia-reperfusion injury without irreversibly compromising the capacity to degrade oxidized proteins. Selective inhibition of 26S proteasome-directed proteolysis is also possible with inhibitors targeting ATPases in the 19S complex (45) . In contrast to the array of inhibitors, there are fewer pharmacological activators for proteasomes currently available. Synthetic 19S COOH-terminal peptides, which release the functional latency of proteasomes, have been successfully engineered; thus a new generation of activators is likely on the horizon (79) . Small molecule activators are also emerging (39) . These may offer unprecedented therapeutic benefits in cardiac diseases where misfolded proteins accumulate.
Proteasomes Amidst a Diseased Cardiac Proteome
Proteasome dysfunction has been identified in numerous cardiomyopathies, including but not limited to ischemic injury (67), hypertrophy (86), desmin-related cardiomyopathy (46) , and hyperglycemia-induced cardiomyopathy (68) . Both attenuation and enhancement of ATP-dependent and ATP-independent proteasomal activities-in either convergent or divergent directions-have been reported. Alterations in core and regulatory particle expression have also been observed (24, 68, 70) . Although these studies have provided novel and important insights into proteasomecentric changes correlated with disease, the critical questions remaining are: How are substrate selectivity and specificity affected by these changes in proteasomes, and, ultimately, how does this affect cardiac phenotype? As discussed below, proteasomal degradation of key cardiac proteins can either diminish or enhance flux through various cardiomyocyte signaling pathways. Consequently, proteasomes may be considered as central regulators of cardiac remodeling in the diseased heart and thus may present as important therapeutic targets.
Failing hearts are encrusted with soluble amyloidcontaining oligomers thought to be toxic entities preceding the formation of insoluble aggregates (76) . These aberrant protein aggregates contain intermediate filaments, ubiquitin, and proteasome subunits, and they herald cardiac dysfunction. A hallmark of cardiac hypertrophy is the disproportionate increase in sarcomeres, either in parallel (concentric hypertrophy) or in series (eccentric hypertrophy) (74) . Atrogin-1 and MUscle-specific RING Finger proteins (MURFs) are E3 ligases specific to skeletal and cardiac muscle that are participatory in degrading sarcomeric proteins. MURF-1 targets cardiac troponin I (44), and MURFs-1 and -2 are redundant binding partners for titin, nebulin, troponin T, and myosin regulatory light chain (93) . Interestingly, atrogin-1 displays selectivity for a familial hypertrophic mutant of cardiac myosin binding protein-C over the wild-type form, whereas MURF-1 facilitates degradation of both forms (51), thus illustrating the multifaceted regulation of sarcomere protein turnover. Sarcomere protein turnover is significantly altered in cardiac diseases (97) ; however, mechanisms are not intuitively straightforward. For example, myosin heavy chain, the major thick filament protein, is degraded at a higher rather than lower rate during pressure overload-induced hypertrophy (55) , and actin, the major thin-filament protein, is oxidized and removed via ubiquitin-independent degradation during ischemia/reperfusion (21) .
As versatile mediators of cardiac signaling, regulation of cytosolic proteins by proteasomes is paramount. Calcineurin and NFAT, for example, are critical components of the hypertrophic response and are known targets of proteasomal degradation (85) . Although proteasome inhibition during pressure overload attenuated hypertrophy in vivo (34) as described above, proteasome inhibition in isolated cardiomyocytes and mouse hearts induced calcineurin-dependent nuclear transactivation of NFAT and detrimental changes in cell morphology (85) . This underscores the importance of carefully tailoring treatment regimes of proteasome inhibitors. Activation of cAMP binding response element protein (CREB) in myocytes is central to the ␤-adrenergic pathway. In a recent report, oxidative stress (H 2 O 2 ) induced degradation of CREB by proteasomes, illustrating a mechanism of regulating ␤-adrenergic responsiveness via oxidative potential (63) .
Pronounced ER development is observed in heart failure (47) , where substantial stress is imposed by prolonged acceleration of protein synthesis (61) . Proteasomes are critical for ameliorating ER stress via ER-associated degradation (ERAD) (38) . Prolonged proteasomal inhibition evokes ERinitiated apoptosis via a CHOP-dependent mechanism (28) . Maintaining or strengthening ERAD machinery, of which proteasomes constitute a major player, may be an effective therapeutic strategy in cardiac disease. Alterations in the organization of the sarcoplasmic reticulum (SR) and expression of calcium handling proteins (6) occur in HF. Ryanodine receptors (RyR) are targets of rapid proteasomal degradation during ischemia/reperfusion (65). An important junctional SR regulator of RyR function, triadin-1, is a direct proteasomal target when in an unglycosylated form (54) . Under elevated oxidative stress, both SERCA2a and inositol 1,4,5-triphosphate receptors (IP 3 Rs) are rapidly degraded by proteasomes, the former in a calreticulin-dependent manner (40, 49) .
Alterations in T-tubules, sarcolemma, and gap junctions are also characteristic in heart failure (3, 78) . Proteasomes degrade G-protein receptor kinases (GRKs), which catalyze ␤-adrenergic receptor internalization via ␤-arrestin, thus altering receptor sensitivity (75) . In heart failure, enhanced GRK expression levels and activities have been observed; consequently, ␤-adrenergic receptor density is decreased (23) . Conversely, in ischemia-reperfusion, GRK2 levels are reduced. Treatment with the proteasome inhibitor Bortezomib spared GRK2 levels and normalizes an otherwise augmented isoproterenol sensitivity that imparted cardioprotection against ventricular arrhythmias (95) . In differentiating myotubes, levels of sarcolemmal ␤-catenin are modulated via Ozz E3 ligase, suggesting control of adherens junctions via proteasome-dependent pathways (60) . Connexin levels are tightly regulated by proteasomes (5), and junctional remodeling occurs rapidly post-MI (50), suggesting a localized regulation by the proteasomes. In neurons, synaptic activity is directly correlated with proteasome activity via an L-type channel Ca 2ϩ entry-and CamKII-dependent mechanism (22) . If relevant in cardiomyocytes, this may suggest that the activities of sarcolemmal-associated proteasomes may be rhythmically regulated in response to an altered influx of calcium.
Many pathogenic transcription factors in the nucleus are regulated by the proteasomes. The abundance of p53 is increased in ischemic-induced heart failure due to the downregulation of CHIP ligase and, in turn, decreased proteasomal degradation of p53 (58) . Mdm2 ligase also influences the stability of p53, suggesting multifaceted control of this essential pro-apoptotic protein (19) . The inducible cAMP early repressor (ICER) accumulates in C2C12 cells treated with proteasome inhibitors, demonstrating the impact of proteasomes on the kinetics of the cAMP-inducible transcriptional response (26) . Hypoxia-inducible factor-1 alpha (HIF-1␣), is rapidly degraded by proteasomes on proline hydroxylation in its oxygen-sensing domain-a trigger for ischemiainduced signaling (9) . Moreover, the degradation of IB and subsequent activation of NFB during reperfusion injury is blunted via intravenous administration of proteasome inhibitors (71) . Taken together, these studies demonstrate a critical role of the ubiquitin-proteasome system in kinetically fine-tuning transcriptional responses in cardiomyocytes.
Mitochondria host essential regulators of apoptosis, a hallmark of cardiac diseases. Proteasomes do not appear to bind directly to mitochondrial membranes; however, it is clear that proteasomes act coordinately to degrade many mitochondrial proteins. The beneficial effects of ischemic preconditioning can be blocked by inhibiting proteasomal degradation of PKC␦, a pro-apoptotic kinase responsible for detrimental mitochondrial signaling (13) . Proteasome inhibition in nondiseased myocytes leads to the accumulation of p53 and Bax; therefore, proapoptotic proteins are basal targets of proteasomes (86) . Proteasomal activity is also required to degrade the autoinhibitory NH 2 -terminal domain of pro-apoptotic Bid to activate this potent pro-apoptotic factor (83) . Conversely, in cancer cells, the anti-apopototic protein Bcl-XL is specifically targeted by proteasomes (64) . The apoptosis repressor with caspase recruitment domain (ARC), a mediator of apoptosis during cardiomyocyte stress, is a target of proteasomes (1). Taken together, these studies indicate that the regulatory tone of pro-apoptotic and anti-apoptotic factors is under proteasomal control, and therefore manipulation of proteasomes will likely modulate myocyte death pathways and thus may have profound clinical significance.
Where Are We and Where Do We Need to Be?
Concerted efforts aimed at the molecular characterization of cardiac proteasomes have provided valuable insights into the diverse venues of proteasomal regulation (e.g., inducible subunit expression). Nevertheless, full delineation of the many roles of proteasomes in driving cardiac phenotypes requires an integrated understanding of the dynamics of proteasome complexes and the substrate pools within which they act, since these are not static entities. Four main areas of proteasome biology within cardiac physiology remain elusive. First, there is a lack of subcellular compartmentalization information. Unlike the majority of proteins that primarily function in one, possibly two, microdomains, proteasomes must scaffold within close proximity to many discrete cellular foci to exert precise and time-sensitive function. This becomes increasingly important when targeting proteasomes with therapeutics, since the transformation of distinct cardiac subproteomes may require activation or inhibition of a specific, rather than global, population of proteasomes. Discrepancies in the literature with respect to therapeutic efficacy likely involve the (non)specificity of certain pharmacological interventions. Second, there is a lack of quantitative data regarding the stoichiometry of proteasome complexes in the heart. Thus the relative contributions from functional complexes, or "zomes," to reshape the cardiac proteome are unknown. However, it is obvious that the dynamics of assembly are readily tunable and highly relevant to biological phenotypes. In support of this notion, ␥-interferon evoked a redistribution of proteasome subtypes (i.e., 11S-containing and hybrid proteasomes increased and 19S-containing proteasomes decreased) with little change in the overall protein abundance of proteasome subunits (73) . Each zome (20S, 26S, 11S, hybrid) exhibits apparent distinction with respect to ATP dependence and substrate preference. Tracking how the relative distribution of zomes shifts in parallel with cardiac pathogenesis will provide mechanistic insights on the adaptation of proteasomal degradation capacity to meet demands imposed by disease-induced alterations in substrate repertoires. Third, we have inadequate models to scrutinize the multifaceted regulation of proteasome complexes. As discussed previously, proteasome biology is regulated by expression levels of conventional vs. inducible subunits, regulatory complexes, associating partners, and subcellular location; thus to experimentally isolate and exploit a particular regulatory mechanism faces challenges. For example, transgenic overexpression or knockdown of proteasome subunits initiates changes in both the overall assembly of proteasomes and in the ratio of constitutive vs. immunoproteasomes, thus confounding experimental readouts. Continued efforts aimed at the development of specific inhibitors to either constitutive or immunoproteasomes in combination with transgenic models will offer alternative strategies for dissecting individual regulatory roles. Fourth, previous research efforts have focused mainly on proteasome-centric characterization; thus our understanding of the diverse mosaic of substrate repertoires in both health and heart disease (e.g., expression of novel, disease-specific proteins; altered abundance of proteins; and disease-specific PTMs) remains fragmentary. Substrate affinities of proteasomes are altered by properties embedded within substrates themselves, suggesting that substrates play an active role in the (dys)regulation of their degradation. Elucidating the interplay between altered proteasome features and modified substrate repertoires within the context of cardiomyopathies, where aberrant, misfolded, or de novo disease-specific proteins abound, should certainly be of profound clinical significance (FIGURE 2). Ⅲ FIGURE 2. FIRST AID response of protein degradation machinery to the normal and diseased cardiac proteome
The effective surveillance of protein degradation and protein quality control is an essential determinant of cardiac health or disease. The proteasome acts in concert with lysosomal (autophagy-dependent or -independent) and other protease-specific pathways within the cardiomyocyte; however, knowledge of how these pathways interplay is severely limited. Delineation of these relationships and integration of signaling by the various proteolytic pathways will clarify strategies for the design of effective therapeutics to combat cardiac disease.
